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ABSTRACT
 
Objectives:
 
To assess preference and willingness-to-pay
(WTP) for the insulin mixture Humalog Mix25 relative to
Humulin 30/70, from the patients’ perspective, the rela-
tive importance of individual treatment attributes was
also determined. Differences among ﬁve European coun-
tries were investigated.
Methods: Two hundred and ninety patients with type 2
diabetes were recruited from ﬁve European countries. Of
these, 235 were suitable for inclusion in the analysis.
Their mean age was 51.3 years and, on average, patients
had had diabetes for 11 years. A discrete-choice conjoint
analysis was conducted using face-to-face interviews.
Treatment attributes, such as timing of injections around
meals, 2-hour postprandial control, effect of prandial
dosing, frequency of nocturnal hypoglycemia, and cost,
and levels were derived after a systematic review of all
published comparative clinical trial data. Meta-analyses
were undertaken where appropriate.
Results: Ninety percent (95% CI 86–93%) of patients
would choose Humalog Mix25 over Humulin 30/70, at
the same cost. On average, European subjects were will-
ing to pay €111 per month more for Humalog Mix25
(95% CI €86.71–156.91). The primary driver was the
reduced risk of nocturnal hypoglycemic events, contrib-
uting 49% of WTP. The convenience of dosing immedi-
ately before the meal contributed 37%. Preference results
were similar in all ﬁve countries, although WTP and sen-
sitivity to increasing cost both varied.
Conclusions: Patients in all countries showed a prefer-
ence and WTP for Humalog Mix25 over Humulin 30/70.
The main drivers of patient WTP may be of interest to
pharmaceutical prescribers, manufacturers, and reim-
bursement agencies.
Keywords: insulin, type 2 diabetes, Humalog Mix25,
Humulin 30/ 70, discrete choice experiment, willingness-
to-pay, cost beneﬁt analysis.
 
Introduction
 
The aging of the population and a worsening risk
proﬁle predict that the prevalence of type 2 diabetes
will continue to increase. When poorly controlled,
diabetes results in prolonged elevation of blood glu-
cose, placing the patient at increased risk of cardi-
ovascular disease, renal disease, amputation,
blindness, and impotence. Advances in diabetes
pharmacotherapy should not only improve glyc-
emic control per se
 
,
 
 but should also aim to maxi-
mize the effectiveness of medication by increasing
patient compliance.
Health-care prescribers and reimbursement agen-
cies should consider patient preferences regarding
diabetes medication, because these are likely to
translate directly to increased compliance, which in
turn will lead to greater treatment effectiveness and
ultimately less burden of disease––to both patient
and society. Patient preference depends not only on
the clinical efﬁcacy differentials among treatment
options, but also patient-relevant characteristics
such as the nature, frequency and convenience of
administration, and the likelihood, severity and
importance of adverse reactions. A formal valuation
study provides the opportunity to quantify the value
of all of these characteristics simultaneously, in
monetary terms.
A wide variety of insulin treatments are now
available, with many patients ﬁnding it convenient
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to use manufactured mixtures of short- and inter-
mediate-acting insulins, because they do not need to
self-mix insulins or to inject twice. Mixtures of
either insulin lispro or human insulin are available.
Insulin lispro provides a greater physiological
response, with the onset of activity occurring within
15 minutes of administration, compared with 30 to
45 minutes for regular human insulin [1]. Similarly,
serum insulin levels peak earlier with insulin lispro
(about 1 hour vs. 2–3 hours) and the duration of
action is shorter than that of human insulin (3.5–
4.5 hours vs. 5.5–7.5 hours).
Humalog Mix25 consists of a 1:3 ratio of short-
acting insulin lispro to intermediate-acting insulin
lispro protamine suspension (also known as neutral
protamine lispro, NPL). Glucose clamp measure-
ments conﬁrm that Humalog Mix25 retains the
rapid action of lispro and the intermediate action of
NPL [2].
Several randomized, controlled clinical trials
have directly compared the efﬁcacy and safety of
Humalog Mix25 with the human insulin mixture,
Humulin 30/70, in patients with type 2 diabetes [3–
5]. Patients in these studies were treated with equiv-
alent mean doses and management was otherwise
comparable. It was concluded from these studies
that Humalog Mix25 produces better postprandial
glucose control than Humulin 30/70, with a lower
rate of nocturnal hypoglycemia. Furthermore, the
pharmacokinetic properties of the two treatments
result in differences in the timing of insulin injec-
tions, with Humalog Mix25 able to be injected
closer to mealtime.
A patient preference and willingness-to-pay
(WTP) study was conducted to value these clinical
and convenience features. Valuation studies allow
“value for money” decisions regarding health inter-
ventions to consider both clinical and nonclinical
characteristics.
 
Patients and Methods
 
Patients
 
A total of 290 patients were enrolled from France
(n 
 
=
 
 53), Germany (60), Italy (56), Spain (60) and
the UK (61). Inclusion criteria were: more than 18
and less than 70 years of age; diagnosed as having
type 2 diabetes; receiving regular insulin mix injec-
tions for at least 6 months; and currently receiving
regular insulin mix injections. Informed consent
was obtained from all participants and no names of
respondents were collected, hence all data were de-
identiﬁed. A patient rather than societal perspective
was used in the current study, because the investi-
gators considered that an understanding of the dis-
ease and its treatment was paramount.
 
Methods
 
A discrete choice analysis survey was used in the
current study. Discrete choice experiments are a
well-accepted methodology for valuing the relative
beneﬁt of therapies as an incremental WTP. This
value can then be utilized in a cost–beneﬁt economic
evaluation to help policy makers decide whether a
new therapy should be adopted or rejected. A ther-
apy can be considered worth adopting if the net
costs are less than the net beneﬁts, expressed in
monetary terms, although the net beneﬁt of a health
intervention should ideally be ranked with other
interventions competing for ﬁnite funding resources
in health care.
In addition, the technique allows the relative con-
tribution of the individual attributes to total WTP
to be quantiﬁed. Recently, the technique has been
applied to a variety of health interventions [6–13].
Ryan provides a comprehensive review of the use of
discrete choice experiments in the health-care arena
[14]. Telser and Zweifel discuss the theoretical
background and soundness of discrete choice exper-
iments in their recent application of the technique
[11].
The survey was conducted by an independent
research agency (Martin Hamblin GfK) using
face-to-face individual interviews with the aid of a
transcript. The ﬁrst section of the questionnaire
collected demographic data and information relat-
ing to the patient’s disease and treatment habits.
The second section presented 10-paired scenarios.
Each pair of scenarios comprised a ﬁxed sce-
nario, which represented Humulin 30/70 treat-
ment, and an alternative scenario generated from
various combinations of Humalog Mix25, Humu-
lin 30/70, and additional sensitivity levels. The
following ﬁve attributes were included in each
scenario: timing of injection around meals, 2-hour
postprandial control, effect of prandial dosing,
frequency of nocturnal hypoglycemic events, and
cost.
The two scenarios presented within the pair were
labeled anonymously as insulin A and B, and par-
ticipants were asked to indicate in writing their
choice between the two insulin mixtures. These
comparisons were designed to elicit trade-offs from
the participants in order to determine their prefer-
ences. Each participant compared 10 pairs of sce-
narios in the order that they were presented to
them. An example scenario pair is illustrated in
Appendix A, where insulin B represents the ﬁxed
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scenario and insulin A represents one of the gener-
ated alternative scenarios.
The attributes and levels relating to the clinical
characteristics of Humalog Mix25 and Humulin
30/70  were  derived  after  a  systematic  review  of
the available published articles and conference
abstracts that reported head-to-head comparisons
of these two insulin preparations (located by
Medline and Embase searches conducted in July
2001). Publications and abstracts were also sourced
from the manufacturer.
To meet the inclusion criteria, a study had to: be
a randomized, controlled clinical trial of Humalog
Mix25 versus Humulin 30/70; report data for type
2 diabetics; be of minimum 3-months treatment
duration; have no fewer than 10 patients per treat-
ment arm; and report data for 2-hour postprandial
blood glucose concentration and/or nocturnal
hypoglycemic events. Three studies met the inclu-
sion criteria. Two were published as full-length arti-
cles [3,4] while at the time of this study, the third
was published in abstract form only [5].
The clinical attribute levels were determined
from these studies. Where data for a particular
attribute were available from more than one of the
studies, a meta-analysis was conducted using Rev-
Man 4.1 to obtain a statistically pooled result. A
ﬁxed-effects model was applied, except in the case
of statistically heterogeneous results, where a ran-
dom-effects (RE) model was used. Pooled means for
individual treatment arms were calculated using the
weightings indicated in Fig. 1. Pooled estimates
indicated a statistically signiﬁcant treatment effect
for both 2-hour postprandial blood glucose and
nocturnal hypoglycemia rate. Therefore, it was
appropriate to include both as attributes in the dis-
crete choice experiment. Other clinical attributes
not reaching statistical signiﬁcance were not
included in the discrete choice experiment.
In addition, patient-relevant differences in
 
Figure 1
 
(a) Pooled 2-hour postprandial blood glucose (adjusted to premeal blood glucose of  9.2) (all available published data)
 
a
 
. (b) Pooled noc-
turnal hypoglycemia rate (all available published data).
(b)
(a)
Comparison: 02 3 mth studies
Outcome:      03 2 hr pp BG 
Study
Roach, 1999 (IODM) 63 9.96 (2.80)
9.09 (2.31)
10.72 (2.35) 37.8
-0.89 [-1.45,-0.34]
-0.97 [-1.67,-0.27]
-0.76 [-1.66,0.14]
62.2
100.0
10.06 (2.48)89
152
63
89
152
-2 20-4 4
Favours controlFavours treatment
Roach, 1999 (IODM)
Total (95%CI)
Test for overall effect z = 3.14 P = 0.002
Test for heterogeneity chi-square = 0.13 df = 1 P = 0.72
Treatment Control WMD WMDWeight
n nmean (sd) mean (sd) (95%CI Fixed) % (95%CI Fixed)
Comparison: 02 3 mth studies
Outcome:      01 Nocturnal hypo rate
Study
Brash, 2001 (IOMD) 81 0.20 (0.80)
0.30 (1.00)
0.50 (1.40) 59.4
-0.30 [-0.57,-0.03]
-0.30 [-0.72,0.12]
-0.30 [-0.65,0.05]
40.6
100.0
0.60 (1.40)63
144
81
63
144
-0.5 0.50-1 1
Favours controlFavours treatment
Roach, 1999 (IODM)
Total(95%CI)
Test for overall effect z = 2.17 P = 0.03
Test for heterogeneity chi-square = 0.0 df = 1 P = 1
Lispro Mix 25 30/70 WMD WMDWeight
n nmean (sd) mean (sd) (95%CI Fixed) % (95%CI Fixed)
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administration characteristics were also included as
attributes. The selection of these attributes was
made after a pilot survey conducted with type 2 dia-
betic patients in the UK. The pilot involved a qual-
itative study of 13 patients in the UK. A structured
interview presented potential differentiating treat-
ment attributes and hypothetical costs. All statisti-
cally signiﬁcant clinical attributes identiﬁed in the
literature search were found to be of interest to the
subjects, including the timing of the injection before
the meal. The majority of patients admitted to
injecting their current insulin at or after mealtime,
despite this being contrary to instructions.
A third level was included for three of the
attributes to facilitate the conduct of a sensitivity
analysis (see Table 1).
Costs were framed in terms of additional “out-
of-pocket” cost to the subject. The ﬁxed scenario
(i.e., Humulin 30/70) is a no-cost option to subjects,
while the alternative scenarios were randomly
assigned an incremental cost of €0, €10, €20, €30,
€50, or €80 per month. The cost levels were chosen
on the basis that the upper level was selected in the
pilot study and that a reasonable range was
assigned from zero.
The range of scenarios was generated by the pres-
entation of all possible combinations of attribute
levels. Mandatory linkages existed between levels in
attributes 1 and 3, necessitating the exclusion of
nonlogical scenarios (i.e., level 1 in attribute 1 could
be presented only with level 1 of attribute 3, and,
levels 2 and 3 of attribute 1 could be presented only
with level 2 of attribute 3). In fact this makes the
third attribute completely confounded with the ﬁrst,
and hence the third attribute was removed from the
analysis completely. This reduced the number of
scenarios from 54 to 27, one of which was the ﬁxed
scenario (representing Humulin 30/70). It was
necessary to then exclude any scenarios where all
attributes for the ﬁxed scenario are preferable to
those of the alternative scenario. In this situation,
choosing the alternative (worse) scenario with a
higher cost would be illogical. After exclusion of
these “dominated” scenarios, a total of 19 alterna-
tive scenarios remained. One of these was the base-
line alternative scenario (representing Humalog
Mix25), leaving 18 other scenarios available for
randomization.
It is impossible to generate an orthogonal design
from the remaining scenarios so two designs were
produced instead. Each design included the baseline
alternative scenario and eight other scenarios cho-
sen at random from the 18 remaining scenarios.
Each set was presented alongside the ﬁxed scenario
to half the sample in each country. One additional
scenario pair was presented to all participants. This
was an illogical scenario in which the alternative
scenario duplicated the ﬁxed scenario, but the alter-
native scenario was associated with a cost of €20.
This approach is commonly used to pick up so-
called irrational traders, those prepared to pay more
than the minimum for the same scenario with dif-
ferent prices. The 10 scenario pairs were presented
to subjects in a randomly determined order.
 
Table 1
 
Levels for noncost attributes and their source
 
Source
Attribute 1: Timing of  injection before meal
Level 1 0–15 min (alternative scenario)
 
‡
 
Humalog Mix25 Product Information
Level 2 30–45 min (ﬁxed scenario)
 
‡
 
Humulin 30/70 Product Information
Level 3 60 min Additional level for sensitivity analysis
Attribute 2: Two-hour postprandial blood glucose
Level 1 9.4 mmol/L (alternative scenario)
 
‡
 
Weighted average level for patients treated with Humalog Mix25, estimated by
meta-analysis of  available clinical evidence [3,4]*
Level 2 10.3 mmol/l (ﬁxed scenario)
 
‡
 
Weighted average level for patients treated with Humulin 30/70, estimated by 
meta-analysis of  available clinical evidence [3,4]*
Level 3 11.0 mmol/L Additional level for sensitivity analysis
Attribute 3: Effect of  prandial dosing
Level 1 Won’t make a difference Pharmacokinetic data
Level 2 Will make a difference Pharmacokinetic data
Attribute 4: Nocturnal hypoglycemic frequency
Level 1 One event in 12 months (alternative scenario)
 
‡
 
Weighted average rate for patients treated with Humalog Mix25, derived from 
meta-analysis of  available clinical evidence [4,5]
 
†
 
Level 2 Two events in 12 months (ﬁxed scenario)
 
‡
 
Weighted average rate for patients treated with Humulin 30/70, derived from 
meta-analysis of  available clinical evidence [4,5]
 
†
 
Level 3 Four events in 12 months Additional level for sensitivity analysis
 
*Weighted mean difference from the meta-analysis (
 
-
 
0.89, 
 
P
 
 
 
=
 
 0.002) was applied to a premeal value of  9.2 mmol/L. The value from Roach et al. [4] is 
 
PM
 
 value only;
Roach et al. [3] value is pooled 
 
AM
 
 and 
 
PM
 
 value.
 
†
 
Weighted mean difference from the meta-analysis (
 
-
 
0.30 per 3 months, 
 
P
 
 
 
=
 
 0.03).
 
‡
 
Alternative and ﬁxed scenarios constituting the primary analysis of  Humalog Mix25 and Humulin 30/70.
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Note that the classical approach to this type of
study dictates the use of orthogonal designs for rea-
sons of statistical efﬁciency and convenience. When
used for a linear model, the advantages include
higher statistical efﬁciency, or smaller variance esti-
mates, and uncorrelated estimates, so that coefﬁcient
estimates are those obtained using unadjusted anal-
yses. Nevertheless, logistic regression modeling is
being used to analyze the responses, so that the
resulting variance matrix for the estimated coefﬁ-
cients is generally not diagonal, that is, coefﬁcients
are not uncorrelated. Also, the ultimate efﬁciency of
any design is a function of the unknown regression
coefﬁcients, which may result in an overall drop in
efﬁciency when compared to nonorthogonal designs.
We therefore see little disadvantage in our approach.
 
Statistical Methods and Other Data Analysis Issues
 
Descriptive statistics were performed on the demo-
graphic responses. For continuous outcomes, means
and standard deviations were calculated. For cate-
gorical responses, frequency tabulations were pro-
duced. All statistical analyses were performed using
Stata version 6.0 (Stata Corporation, College Sta-
tion, TX, 1997) [15].
A number of methods have been proposed to
estimate the relative utilities for the attributes of
interest in stated preference studies with a binary
choice response. These include conditional and RE
logistic regression, a multivariate binary (MVB) dis-
tribution, and generalized estimating equations
(GEE [16]). The latter approach is used for the fol-
lowing reasons.
With independent binary outcomes and predic-
tors or covariates measured for each outcome, logis-
tic regression is the standard regression method of
choice [17]. We regard this as the ideal sampling
approach for our type of study, as it maximizes the
variability in the responses, for the given scenario
information. Strict implementation of this approach
leads to a survey design where each subject is pre-
sented with a single scenario. Nevertheless, as logis-
tics and cost usually preclude this, in practice each
subject responds by making a choice for each of a
set of scenarios. This approach results in correlation
between a subject’s responses, unwanted correlation
given the ideal approach, which must be accounted
for in any analysis.
The method of GEE was developed for precisely
this situation in analyses based on generalized linear
models, of which logistic regression is an example,
and interpretation of the coefﬁcients is the same as
in standard logistic regression. The philosophy of
the other approaches, RE and MVB, differs, as the
underlying assumed models have a different genesis.
Coefﬁcients estimated by the other models do not
have the same interpretation [18]. The RE model,
assumes an underlying, subject-speciﬁc propensity
to choose in favor of one outcome, which is random
between scenarios. Under this model, it is this prop-
erty, which induces a correlation between a subject’s
responses. In RE and conditional logistic regression,
the attribute coefﬁcients are estimated simultane-
ously with the propensity, which is usually unob-
served. This is a different model from the
corresponding standard logistic regression model,
and thus has a different interpretation. More obvi-
ously, they have different magnitudes.
A MVB model is potentially very complex and
hard to interpret. Here the assumption is that a
model described by the attribute effects and param-
eters that describe the correlation structure typically
arise simultaneously in the same (log- or logit-) lin-
ear model [18]. In this case the attribute effect coef-
ﬁcients are adjusted for the correlation structure
effects. Again, it is easy to see that such a model is
different from a standard logistic regression model,
so that the interpretation of coefﬁcients is different.
GEE estimation is based on iteratively re-
weighted least squares estimation, where an
assumed correlation structure between an individ-
ual’s outcomes forms part of the weight matrix for
an individual’s data. Parameter estimates and cor-
responding variance (standard error) estimates may
be affected by misspecifying the correlation struc-
ture, but a robust or sandwich-estimator of variance
estimates may be used to guard against this [19].
Willingness-to-pay (WTP) for the various
attribute levels is calculated in a straightforward
manner from the estimated coefﬁcients, dividing the
negative of the estimated attribute level coefﬁcient of
interest by the coefﬁcient of cost. The rationale
underlying this approach is derived from Lancaster’s
theory of demand, in which these ratios are known
as marginal rates of substitution [20]. The WTP for
a speciﬁc scenario is then the sum of the individual
WTP for the corresponding attribute levels.
Conﬁdence intervals for WTP are not routinely
available from the GEE procedure, and the distri-
bution of the resulting WTP is unknown. A number
of methods have been used including Fieller’s
method, the delta method (based on a Taylor’s series
expansion about the true value) [21] and, more
recently, bootstrapping [22]. We adopted bootstrap-
ping of conﬁdence intervals as the preferred
approach as this method makes no assumptions
about the distribution or variability of WTP, unlike
the other methods, and is thus robust to challenges
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about the sampling distribution. Conﬁdence inter-
vals are based on a so-called bootstrap distribution,
which is obtained by estimating the desired statistic
on a series of random samples from the observed
data set, samples that are made with replacement.
Observed bias in the mean of the bootstrap distri-
bution is adjusted for by the so-called bias correc-
tion method. Conﬁdence intervals for WTP were
calculated using bootstrap distributions of 2000
samples analyzed by key logistic regression models
using GEE.
In this study, the attribute referring to the effect
of prandial dosing (Attribute 3) was not considered
sufﬁciently independent of the ﬁrst attribute refer-
ring to the time of dosing. It was therefore omitted
from the WTP calculations.
The probability of selecting the proposed treat-
ment relative to the existing treatment at zero incre-
mental cost was calculated. This process was then
repeated at a variety of incremental costs to obtain
a cost-demand curve. In addition to a total incre-
mental WTP, logistic regression enables WTP to be
estimated for all contributing attributes and there-
fore also allows the relative importance of the
attributes to be gauged.
A simple sensitivity analysis is conducted in order
to detect the extent to which the demographics of
the sample may have confounded the results of the
discrete choice model, and thus affect WTP. Step-
wise logistic regression analysis is used to determine
any signiﬁcant demographic variables, in addition
to the scenario attributes. Currently an arbitrary
limit of 20% difference between adjusted and unad-
justed models as the threshold above which poten-
tial reasons for differences should be considered
more carefully. Further research into this approach
is needed.
 
Results
 
Demographics
 
Participants appeared representative of European
type 2 diabetics, with the exception of elderly
patients (
 
>
 
 65 years), who were under-represented
 
Table 2
 
Categorical participant demographics
 
Characteristic Category n %
Age
 
<
 
18 years 1 0.3
18–30 years 18 6.3
31–54 years 123 42.7
55–65 126 43.8
 
>
 
 65 years 20 6.9
Gender Female 157 54.3
Male 132 45.7
Marital status Never married 51 17.6
Married/de facto 176 60.9
Widowed/divorced/separated 62 21.5
Highest educational level Some high school 89 30.8
Completed high school 70 24.2
Trade/technical college 40 13.8
University 70 24.2
Other 20 6.9
Employment status Employed 98 35.4
Self-employed 29 10.5
Full-time homemaker 42 15.2
Unemployed 30 10.8
Retired 78 28.2
Gross annual income Less than €20,000 equivalent 112 41.0
€20,000–40,000 equivalent 112 41.0
€40,000–60,000 equivalent 40 14.7
€60,000–80,000 equivalent 8 2.9
Greater than €80,000 equivalent 1 0.4
Private health insurance Yes 98 33.8
No 192 66.2
Out-of-pocket expense per month 0 199 69.6
Less than €10 equivalent 27 9.4
€10–49 equivalent 40 14
Greater than 
 
€
 
50 20 7
Inject just before meal rather than 30 min before Never 107 37
Occasionally 65 22.5
Often 35 12.1
Always 82 28.4
Inject just after meal rather than 30 min before Never 194 67.4
Occasionally 81 28.1
Often 9 3.1
Always 4 1.4
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(Table 2). The mean age of patients was
51.3 years (SD 12.7) and they had had diabetes
for an average of 11.0 years (SD 9.3). The major-
ity of patients fell within the lower two income
brackets (
 
£
 
€
 
40,000). This is to be expected given
the high proportion of semiretired or retired par-
ticipants in this patient population. The majority
of patients (70%) did not contribute ﬁnancially to
the cost of their diabetes treatment. This reﬂects
the health and welfare arrangements of the partic-
ipant countries.
Three of the demographic characteristics were
found to have a signiﬁcant effect on the results.
Those patients with private health insurance were
willing to pay more, as were those patients who
had had diabetes for a longer period of time.
The frequency of injecting after meals also inﬂu-
enced the WTP, but there was no consistent
directional trend across the categories. Neverthe-
less, when the GEE model for all countries
combined was adjusted for these signiﬁcant
demographic effects, the estimates of WTP were
similar to those for the unadjusted model. The
conﬁdence intervals based on this model were
also quite similar. It was therefore concluded that
the confounding introduced by these factors was
minimal, and hence the unadjusted results are
presented here. With regard to individual coun-
tries, only the UK model required adjustment for
demographic factors.
 
Irrational Traders and Nontraders
 
In one scenario pair, presented to all participants,
the alternative scenario duplicated the ﬁxed sce-
nario, but was associated with a cost of 
 
€
 
20.
Thirteen respondents chose the most expensive of
this pair and were determined to be “irrational
traders.” Forty-two respondents were not willing
to “trade” under any conditions and were termed
nontraders. These nontraders were typically
patients who always chose the no cost option
regardless of any other considerations. Because
the validity of the discrete choice experiment
method is dependent on sagacious trading among
all treatment attributes, including cost, it is com-
mon practice [23] to exclude both irrational trad-
ers and nontraders from the analysis, and this
approach is adopted here. It is noted, however,
that for nontraders this approach may be too con-
servative. Further comments about this are made
below.
 
Patient Preference
 
The statistical comparison of the alternative sce-
nario representing Humalog Mix25 with the ﬁxed
scenario representing Humulin 30/70 is referred to
as the primary analysis. The levels of the ﬁxed sce-
nario were: 30 to 45 minutes for timing of dose,
10.3 mmol/L for the 2-hour postprandial blood glu-
cose level, and two nocturnal hypoglycemic events
every 12 months. The alternative scenario in the
primary analysis was 0 to 15 minutes for timing of
dose, 9.4 mmol/L for the 2-hour postprandial blood
glucose levels, and one nocturnal hypoglycemic
event every 12 months.
Estimated coefﬁcients for the attribute levels,
plus the coefﬁcient of cost, in the logistic regression
unadjusted for demographic factors except for
country of origin, are shown in Table 3. Robust
standard error estimates and estimated 95% con-
ﬁdence intervals are also shown. By convention, the
reference level of each attribute is that for the ﬁxed
scenario. The coefﬁcients of the remaining levels for
each attribute are interpreted as deviations from the
reference level. Note that although most of the
attributes for this study are continuous we have
 
Table 3
 
Estimated attribute levels and cost coefﬁcients, standard errors and conﬁdence intervals for the logistic regression
model, unadjusted for demographic factors
 
Attribute Level Estimate Robust SE
 
P
 
 value* 95% CI
Timing of  injection 30–45 min 0
 
†
 
– – –
before meal 0–15 min 0.912 0.133
 
<
 
0.001 0.652, 1.172
60 min
 
-
 
0.615 0.132
 
<
 
0.001
 
-
 
0.874, 
 
-
 
0.356
Two-hour 10.3 mmol/L 0
 
†
 
– – –
postprandial 9.4 mmol/L 0.360 0.144 0.012 0.078, 0.643
blood glucose 11.0 mmol/L
 
-
 
0.431 0.129 0.001
 
-
 
0.684, 
 
-
 
0.178
Nocturnal 2 events in 12 months 0
 
†
 
– – –
hypoglycemic 1 event in 12 months 1.202 0.141
 
<
 
0.001 0.926, 1.478
frequency 4 events in 12 months
 
-
 
1.302 0.173
 
<
 
0.001
 
-
 
1.640, 
 
-
 
0.964
Cost (per 
 
€
 
)
 
-
 
0.022 0.003
 
<
 
0.001
 
-
 
0.027, 
 
-
 
0.017
 
*
 
P
 
 value for Wald test that the coefﬁcient is 0. Test statistic is calculated as z 
 
=
 
 estimate/robust SE.
 
†
 
By convention, the ﬁxed scenario level of  each attribute was set to 0.
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grouped values into categories for ease of
interpretation.
Based on estimated coefﬁcients, the logit model
equation for calculating the probability of choosing
Humalog Mix25, relative to Humulin 30/70, is:
Logit(p) 
 
=
 
 ln{p/(1 
 
-
 
 p)} 
 
=
 
2.18440.37 
 
-
 
 0.0222596 (incremental cost in 
 
€
 
 
per month) (1)
At zero additional cost, the probability of accepting
the primary alternative scenario (HumalogMix25)
rather than the ﬁxed scenario (Humulin 30/70) was
0.8988 (95% CI 0.8645, 0.9253). This preference
can also be expressed as odds of 8.889 for choosing
Humalog Mix25 (95% CI 6.38, 12.38).
As expected, the preference for Humalog Mix25
decreased with increasing cost: 0.8767 at an incre-
mental cost of 
 
€
 
10 per month, 0.8506 at 
 
€
 
20,
0.8200 at 
 
€
 
30, 0.7449 at 
 
€
 
50, and 0.5996 at 
 
€
 
80
per month. If the premium were approximately
 
€
 
100 per month, it is estimated that the probability
of choosing Humalog Mix25 would fall to approx-
imately 0.5.
The magnitude of the individual attribute effects
were also determined and presented as odds ratios,
relative to Humulin 30/70. The results of the com-
parison with the primary alternative are presented
in Table 4. In addition, the effect of cost per se on
preference is presented for every incremental euro
per month.
 
Willingness-to-Pay
 
The results indicate that individuals in all countries
combined were prepared to pay, on average, a total
of  
 
€
 
111  per  month  for  Humalog  Mix25  over
and above the cost of Humulin 30/70. The bias-
corrected  95%  conﬁdence  intervals  give  a  range
of likely values for the true WTP (
 
€
 
86–156 per
month).
The relative importance of the attributes can be
determined in monetary terms from the WTP coef-
ﬁcients. A set of estimates of the incremental cost
that participants were willing to pay for the various
attributes for Humalog Mix25 is shown in Table 5.
Only two demographic factors had a consistent,
statistically signiﬁcant effect on total WTP. The
longer a patient had had diabetes, the greater the
WTP. In addition, patients who held private health
insurance were willing to pay more, although the
magnitude of the difference was modest. Patients
with private health insurance were willing to pay
 
€
 
116.60 (SE: 37.78; 95% CI 65.80, 233.50), while
those without private health insurance were willing
to pay 
 
€
 
106.40 (SE: 19.27; 95% CI 77.10, 156.20).
 
Sensitivity Analyses
Additional attribute levels were included for time of
dosing, 2-hour postprandial blood glucose concen-
tration, and the rate of nocturnal hypoglycemic
events. Table 6 summarizes the WTP values
obtained for Humalog Mix25 in response to
Table 4 Patient preference for Humalog Mix25 relative to Humulin 30/70 for each attribute in isolation, expressed as odds
ratios (unadjusted)
Attribute Humalog Mix25 Humulin 30/70 Odds ratio 95% CI (BC) P value*
Time of  dose 0–15 mins 30–45 mins 2.49 1.92, 3.23 <0.001
Two-hour postprandial blood glucose 9.4 mmol/L 10.3 mmol/L 1.43 1.08, 1.90 0.012
Frequency of  nocturnal hypoglycemic events per 12 months 1 2 3.33 2.52, 4.39 <0.001
Cost (per month) per €1 €0 0.98 0.973, 0.983 <0.001
*P value is obtained from a multivariate Wald test that assumes a normal distribution for the coefﬁcients. In contrast, the conﬁdence intervals are obtained empirically
from the bootstrap observations, and so they do take into account bias.
Abbreviations; BC, bias-corrected for a skewed distribution; CI, conﬁdence interval.
Table 5 Incremental WTP utilities for Humalog Mix25 relative to Humulin 30/70
Attribute Variable
Estimated
WTP (€) SE‡ 95% CI§
Percentage of
aggregate WTP
accounted for
Time of  dose* 0–15 vs. 30–45 mins 40.98 7.07 28.97, 57.48 37%
Two-hour postprandial blood glucose† 9.4 mmol/L vs. 10.3 mmol/L 16.19 6.34 4.87, 29.71 14%
Nocturnal hypoglycemic event rate† One vs. two events per 12 months 54.01 8.26 41.80, 77.05 49%
Total* 111.18 16.56 86.71, 156.91 100%
*1972 successful bootstrap repetitions.
†2000 successful bootstrap repetitions.
‡Standard error of  the bootstrap estimate.
§Bias-corrected conﬁdence interval.
Abbreviations: CI, conﬁdence interval; SE, standard error; WTP, willingness-to-pay.
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changes in attribute levels. The effect of adjusting
for demographics is also presented.
The sensitivity analyses indicated that the WTP
was responsive to changes in levels of all attributes.
The levels tested were worse than those of the ﬁxed
scenario and predictably led to a negative WTP.
This suggests the WTP is a continuum across the
span of levels tested in this study and is a valid
measure of patient preference.
A further sensitivity analysis was conducted to
quantify the effect of excluding nontraders and irra-
tional traders (Table 6).
The results showed that broadening the patient
inclusion criteria to include those who fail to trade
reduced the total WTP by €25.20. This reduction in
WTP is expected, as the majority of nontraders
always choose the no-cost option. In contrast, inclu-
sion of the irrational traders had little effect on total
WTP. This is also expected, as irrational traders
tend to have more varied and less predictable
responses that are usually nonsensical.
Country Differences
The results presented above are the combined
results for the ﬁve countries. When the results for
individual countries were considered, the proba-
bility of choosing Humalog Mix25 at no incre-
mental cost was found to be similarly high in all
ﬁve countries (range: 0.8599–0.9311). Neverthe-
less, as the incremental cost of Humalog Mix25
treatment increased, the probability of choosing
this treatment decreased at different rates in the
ﬁve countries (Fig. 2). Note that pounds were
used for the English survey, and these have been
converted to euros, for ease of comparison. The
French and UK patients exhibited the lowest cost
elasticity, while Italian patients were highly sensi-
tive to cost. Despite all patients being told that
the cost was to be considered in the context of
their “out-of-pocket” expense, it is possible that
historical cultural differences in pharmaceutical
reimbursement had an effect on the patients’
response to cost.
Table 6 Effect of  altered clinical characteristics and altered patient inclusion criteria
Change in alternative attribute level* or patient inclusion criteria
Primary analysis
WTP† (€)
Revised
WTP† (€) 95% CI‡
Change in dosing time from 0–15 mins to 60 mins 40.98 -27.62 -44.02, 15.28
Change in two-hour postprandial blood glucose from 9.4 mmol/L to 11 mmol/L 16.19 -19.36 -33.90, -7.74
Change in frequency of  nocturnal hypoglycemia from one to four events per 12 months 54.01 -58.50 -81.56, -43.40
Result adjusted for demographics 111.18 102.11 77.49, 151.54
Result including nontraders§ 111.18 87.26 62.40, 121.12
Result including nontraders + irrational traders§ 111.18 85.98 61.04, 118.93
*Compared with ﬁxed level.
†Per month.
‡Bias corrected conﬁdence interval.
§n = 42 nontraders, n = 13 irrational traders.
Abbreviations: BC, bias corrected; CI, conﬁdence interval; WTP, willingness-to-pay.
Figure 2 Probability of  choosing Humalog Mix25
rather than Humulin 30/70 with increasing incremental
cost.
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An intercountry difference was apparent in the
total WTP per month (Table 7).
In all countries, the main driver of both prefer-
ence and WTP for Humalog Mix25 was the reduced
frequency of nocturnal hypoglycemic events, closely
followed by the convenience of dosing closer to
mealtime. The extent of the 2-hour postprandial
excursion was of lesser importance to the patients,
only reaching statistical signiﬁcance in Spain.
Discussion
The results of the current valuation study conducted
in ﬁve European countries indicate a strong patient
preference for the attributes of Humalog Mix25 rel-
ative to those of Humulin 30/70. Close to 90% of
all patients preferred Humalog Mix25 when both
treatments were presented with equal cost. This is
comparable to the 84% preference detected by
Dranitsaris et al. [24] using a contingent valuation
technique. The preference for Humalog Mix25 is
not surprising as Humalog Mix25 has advantages
in both clinical and patient-relevant attributes. In
monetary terms, this preference corresponded to an
incremental mean WTP for Humalog Mix25 of
approximately €111 per month. This incremental
WTP was in excess of any monthly costs associated
with Humulin 30/70.
The current study was able to determine that the
primary driver of both patient preference and WTP
was the reduced risk of nocturnal hypoglycemic
events with Humalog Mix25. Patients were more
than 3-times as likely to choose the treatment with
fewer nocturnal hypoglycemic events (Humalog
Mix25), with this attribute contributing 49% of the
total WTP. This was despite the low absolute rate of
events for both treatments (one vs. two nocturnal
hypoglycemic events in a 12-month period). This
reﬂects the patients’ fear of nocturnal hypoglyc-
emia, the extent of which may not always be appre-
ciated by prescribers or reimbursement decision
makers.
The convenience of being able to inject Humalog
Mix25 immediately before mealtime was also
highly valued by patients, contributing a further
37% of the total WTP. As 63% of this representa-
tive sample admitted to injecting just before the
meal and as many as 33% reported injecting after
the meal, the importance of an insulin that can be
injected close to mealtime cannot be disputed.
The improved postprandial glycemic control
made a small contribution to preference and WTP,
failing to reach statistical signiﬁcance in all individ-
ual countries except Spain. As participants were
diabetic patients aware of the long-term sequelae of
hyperglycemia, it is unlikely that they did not appre-
ciate the relevance of 2-hour postprandial blood
glucose excursion per se. Nevertheless, the magni-
tude of the difference tested in the current study
(0.9 mmol/L) was not highly valued.
The majority of demographic factors had mini-
mal effect on WTP. In contrast to previous studies,
income did not signiﬁcantly affect WTP. However,
this may reﬂect the rather homogenous nature of
the patient sample with respect to income. Notably,
patients who had private insurance were willing to
pay more for the beneﬁts of the treatment. This may
be an important consideration in future WTP stud-
ies. If one considers the duration of disease to be a
proxy for the severity of disease (and risk of further
morbidity), then it is not surprising that this was the
other factor inﬂuencing WTP. Patients with a higher
initial risk can be expected to pay more for treat-
ment, in accordance with economic theory [11].
As mentioned to in the Results section, the exclu-
sion of nontraders, although standard, may be ques-
tionable. Some might argue that responses from a
nontrader merely represent an extreme value on
some willingness-to-trade spectrum. This point of
view has some appeal, as the opposite case of data
Table 7 Estimated total WTP and percentage contribution of  individual attributes to total WTP in individual countries
Estimated
total WTP (€) 95% CI*
% contribution to WTP
Nocturnal
hypoglycemic
event rate
Time of
dose
Two-hour postprandial
blood glucose
France 146.83 51.03, 946.31 48 46 6
Germany 126.65 57.89, 243.06 53 40 7
Italy 56.98 18.37, 106.08 41 37 22
Spain 150.06 88.68, 357.13 42 31 27†
UK 194.36‡ 83.82, 2711.96 65 35 0
*Bias-corrected conﬁdence interval. Based on between 1400 and 2000 successful bootstrap repetitions.
†Spain was the only country where the WTP for improved postprandial glycemic control reached statistical signiﬁcance.
‡The WTP for UK is adjusted for demographic factors. All other WTP values are unadjusted.
Abbreviations: CI, conﬁdence interval; WTP, willingness-to-pay.
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from  subjects  who  always  trade  are  not  excluded
in the traditional approach. Nevertheless, the
approach to analyzing the data depends on what
population the researcher wishes to make inferences
about. From a statistical point of view, the result of
excluding nontraders is that the coefﬁcients of the
logistic regression model are estimated from a prob-
ability model, which is conditional on each subject
having traded at least one scenario. Consider the
results from the unadjusted GEE model. The obvi-
ous effect of excluding nontraders is that the inter-
cept (a) will be overestimated compared with the
estimate obtained if nontraders were included. Sup-
pose that d remains the same. Then, to compensate
for this apparent increase in the estimated log-odds
of choosing the ﬁxed baseline scenario, b estimates
will be attenuated, on average, so that the sum of
such coefﬁcients for any scenario will be smaller
(i.e., more negative), and the apparent total WTP
greater. Conversely, the total WTP will be less if
data from nontraders are excluded, as was noted in
the Results section.
On the other hand, an unconditional analysis, in
which no a priori selection of subjects on the basis
of trader status takes place, may be more natural.
One way to achieve this is to assume, as speculated
above, which nontraders and traders arise from the
same population and simply include data from non-
traders in the analysis. Alternatively, one may
assume that two populations are represented in the
sample. One way to analyze such data is to use ﬁnite
mixture modeling. This approach has been used in
the discrete-choice modeling area as a means of
examining market segmentation [25]. The question
of how to apply ﬁnite mixture models to data where
GEE estimation is used is a topic for further
research.
To the best of our knowledge, this study is the
ﬁrst published discrete choice experiment of a
health-care invention conducted simultaneously
across multiple countries. The probability of choos-
ing Humalog Mix25 at no incremental cost was
similarly high in all ﬁve countries. Nevertheless, as
the incremental cost of Humalog Mix25 treatment
increased, the probability of choosing this treatment
decreased at different rates in the ﬁve countries. The
French and UK patients exhibited relative insensi-
tivity to the increasing cost, while Italian patients
were highly sensitive to cost. The German and
Spanish patients showed a more moderate response.
Despite all patients being told that the cost was to
be considered in the context of their “out-of-
pocket” expense, it is possible that historical cul-
tural differences with respect to pharmaceutical
reimbursement had an effect upon the patients’
response to cost. This was reﬂected by the WTP,
which was highly variable among the countries.
These ﬁndings highlight the need for researchers
and policy makers to conduct monetary valuations
of health beneﬁts in each country in question. In
contrast, the results of the current study suggest that
the relative importance of individual attributes was
quite robust across these ﬁve countries.
The choice of estimation using GEE over other
approaches deserves further comment. We have
proposed that the ideal sampling situation leads to
standard logistic regression. Implicit in this view is
the assumption that gathering of information on a
subject’s preference across the complete range of
attribute levels is not essential. If this is not the case,
certainly other approaches need to be explored; as
such a requirement would lead more naturally to
consideration of a multivariate outcome model.
Alternatively, if prediction of choice for an individ-
ual with a known propensity is paramount, then a
RE model is a more natural choice [18].
Conclusions
In conclusion, this study found that respondents
were willing to pay a considerable monthly pre-
mium for the incremental beneﬁts of Humalog
Mix25 relative to Humulin 30/70. This indicates
the extent of welfare perceived by patients from the
reduced risk of hypoglycemia, convenience of the
administration schedule, and improvement in post-
prandial control. The monetary value of Humalog
Mix25 measured in the current study can be com-
pared with the additional acquisition costs for
Humalog Mix25 relative to Humulin 30/70 in these
countries, to indicate the extent of welfare gain to
the community.
The authors wish to acknowledge the editorial assistance
of Alison Hillman and the advice and pilot investigations
of Dr Mark Schulz. This study was funded by Eli Lilly &
Company Ltd.
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Appendix A: Example of scenario pair presented to participants
Attribute Insulin A Insulin B
When to inject 0–15 min before a 30–45 min before a
The recommended time to inject is: meal meal
Blood sugar after meal
Imagine before a meal your blood sugar was
9.2 mmol/L and 2 hours after a meal it is:
11 mmol/L 10.3 mmol/L
Injecting just before a meal
If  for some reason the insulin is used just
before a meal:
This won’t make any difference. After a meal
your blood sugar would be the same as if  you
took the insulin at the correct time
This will make a difference. After a meal
your blood sugar would be higher than if
you took the insulin at the correct time
Night-time very low blood sugar or “hypo”
Using the insulin, you can expect to have:
Two night-time “hypos” over 12 months Two night-time “hypos” over 12 months
Cost to you of  this insulin every month: £18 £0
Which insulin do you prefer? Insulin A:  Insulin B: 
Please tick one box only
